# Atara Biotherapeutics, Inc. (ATRA) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/ATRA
## Company Profile
- Ticker: ATRA
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology, Immunology
## Stock Data
- Close: 9.225 USD
- Market cap: 89200702.8 USD
- Last updated: 2026-08-12
## Business Overview
### Allogeneic EBV T-Cell Platform
Atara Biotherapeutics develops off-the-shelf T-cell therapies generated from healthy donors and directed against Epstein-Barr virus antigens. Its platform does not require T-cell-receptor or HLA gene editing.
### Tabelecleucel
Tabelecleucel, also known as tab-cel or EBVALLO, is an allogeneic EBV-specific T-cell therapy for Epstein-Barr virus-positive post-transplant lymphoproliferative disease. The U.S. application is supported by the pivotal single-arm ALLELE study.
### Partnered Regulatory Model
Pierre Fabre Pharmaceuticals controls the U.S. regulatory and commercial program. Atara supports the BLA resubmission and retains eligibility for an approval milestone, commercial milestones, and tiered royalties.
## Why The Stock Is Moving

The latest monitored company update is “Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress.” The corresponding closing-price reaction is not yet available.

## Drug Assets

- tabelecleucel

## Recent News
- 2026-08-12 20:05 EST — [Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress](https://biopharmsignal.com/news/ATRA/atara-biotherapeutics-announces-second-quarter-2026-financial-results-and-operat-79ba7a52) — Source: Atara Biotherapeutics, Inc.
- 2026-06-12 20:00 EST — [Atara Biotherapeutics Announces Changes to Its Board of Directors](https://biopharmsignal.com/news/ATRA/atara-biotherapeutics-announces-changes-to-its-board-of-directors-7faed22a) — Source: Atara Biotherapeutics, Inc.
- 2026-05-12 20:05 EST — [Atara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational Progress](https://biopharmsignal.com/news/ATRA/atara-biotherapeutics-announces-first-quarter-2026-financial-results-and-operational-progress) — Source: Atara Biotherapeutics, Inc.
- 2026-05-07 12:05 EST — [Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel](https://biopharmsignal.com/news/ATRA/atara-biotherapeutics-provides-regulatory-update-on-tabelecleucel-36f03b9d) — Source: Atara Biotherapeutics, Inc.
- 2026-03-16 20:05 EST — [Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress](https://biopharmsignal.com/news/ATRA/atara-biotherapeutics-announces-fourth-quarter-and-full-year-2025-financial-results-and-operational-progress) — Source: Atara Biotherapeutics, Inc.